Skip to content
Menu

B. Riley Securities Maintains Buy on Microbot Medical, Lowers Price Target to $3

Benzinga Newsdesk 1 day ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

B. Riley Securities analyst Anderson Schock maintains Microbot Medical (NASDAQ:MBOT) with a Buy and lowers the price target from $4 to $3.

B. Riley Securities analyst Anderson Schock maintains Microbot Medical (NASDAQ:MBOT) with a Buy and lowers the price target from $4 to $3.

Read at benzinga.com